MacroGenics, Inc. (MGNX)
3.845
+0.04
(+1.18%)
USD |
NASDAQ |
Sep 25, 15:32
MacroGenics Cash from Operations (TTM) : -63.72M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.72M |
| March 31, 2026 | -69.96M |
| December 31, 2025 | -81.04M |
| September 30, 2025 | -162.47M |
| June 30, 2025 | -72.12M |
| March 31, 2025 | -69.62M |
| December 31, 2024 | -68.37M |
| September 30, 2024 | -58.00M |
| June 30, 2024 | -153.41M |
| March 31, 2024 | -111.02M |
| December 31, 2023 | -78.20M |
| September 30, 2023 | -20.85M |
| June 30, 2023 | 4.976M |
| March 31, 2023 | -42.10M |
| December 31, 2022 | -86.96M |
| September 30, 2022 | -170.59M |
| June 30, 2022 | -175.96M |
| March 31, 2022 | -172.49M |
| December 31, 2021 | -143.83M |
| September 30, 2021 | -95.05M |
| June 30, 2021 | -105.94M |
| March 31, 2021 | -96.79M |
| December 31, 2020 | -111.90M |
| September 30, 2020 | -144.41M |
| June 30, 2020 | -136.12M |
| Date | Value |
|---|---|
| March 31, 2020 | -148.41M |
| December 31, 2019 | -134.27M |
| September 30, 2019 | -123.45M |
| June 30, 2019 | -143.05M |
| March 31, 2019 | -151.94M |
| December 31, 2018 | -153.23M |
| September 30, 2018 | -14.16M |
| June 30, 2018 | -8.535M |
| March 31, 2018 | 18.44M |
| December 31, 2017 | 14.40M |
| September 30, 2017 | -125.77M |
| June 30, 2017 | -44.63M |
| March 31, 2017 | -47.10M |
| December 31, 2016 | -43.68M |
| September 30, 2016 | -39.20M |
| June 30, 2016 | -96.92M |
| March 31, 2016 | -89.16M |
| December 31, 2015 | -13.66M |
| September 30, 2015 | -9.97M |
| June 30, 2015 | -16.47M |
| March 31, 2015 | 4.843M |
| December 31, 2014 | -32.86M |
| September 30, 2014 | -13.88M |
| June 30, 2014 | 1.359M |
| March 31, 2014 | -4.437M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Gilead Sciences, Inc. | 13.55B |
| Xencor, Inc. | -205.81M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |